Clinical Pharmacology and Drug Toxicity — MCQs

Clinical Pharmacology and Drug Toxicity Indian Medical PG Practice Questions and MCQs

Question 171: Dialysis is useful in poisoning with all of the following, EXCEPT:

A. Methyl alcohol
B. Barbiturates
C. Ethylene glycol
D. Copper sulphate (Correct Answer)

Explanation: The effectiveness of hemodialysis in treating poisoning depends on specific pharmacokinetic properties of the toxin. For a drug to be dialyzable, it must have a **low molecular weight, low volume of distribution ($V_d$), low protein binding, and high water solubility.** **Why Copper Sulphate is the correct answer:** Copper sulphate poisoning cannot be managed with dialysis because copper has a **high volume of distribution** and binds extensively to plasma proteins (like albumin and ceruloplasmin) and tissues. Dialysis only removes substances present in the free, unbound form within the intravascular compartment. The definitive treatment for copper poisoning is chelation therapy with **D-Penicillamine**. **Analysis of incorrect options:** * **Methyl alcohol & Ethylene glycol:** These are low molecular weight, water-soluble alcohols with small volumes of distribution [1]. Dialysis is highly effective at removing both the parent compounds and their toxic metabolites (formic acid and glycolic acid) [2]. * **Barbiturates:** Long-acting barbiturates (like Phenobarbital) have low protein binding and low $V_d$, making them amenable to removal via dialysis or hemoperfusion. **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic for Dialyzable drugs (BLAST-ED):** **B**arbiturates (Long acting), **L**ithium, **A**lcohols (Methanol, Ethanol), **S**alicylates, **T**heophylline, **E**thylene glycol, **D**epakote (Valproate). * **Drugs NOT dialyzable:** Digoxin, Benzodiazepines, Opioids, Copper, and Organophosphates (due to high $V_d$ or high protein binding). * **Hemoperfusion** is preferred over dialysis for drugs that are highly protein-bound but have a small $V_d$, such as Carbamazepine or Phenytoin.

Question 172: Pseudotumor cerebri is caused by all except:

A. Hypervitaminosis A
B. Outdated tetracycline
C. Nalidixic acid
D. Digoxin (Correct Answer)

Explanation: **Explanation:** **Pseudotumor cerebri**, also known as **Idiopathic Intracranial Hypertension (IIH)**, is a clinical syndrome characterized by increased intracranial pressure (ICP) in the absence of a space-occupying lesion or hydrocephalus. It typically presents with headache, papilledema, and potential vision loss. **Why Digoxin is the Correct Answer:** Digoxin is a cardiac glycoside used in heart failure and arrhythmias. It acts by inhibiting the Na+/K+-ATPase pump. It has **no known association** with increased intracranial pressure or pseudotumor cerebri. In fact, because the Na+/K+-ATPase pump is involved in the production of cerebrospinal fluid (CSF) in the choroid plexus, its inhibition would theoretically decrease, rather than increase, CSF production. **Why the other options are incorrect:** * **Hypervitaminosis A:** Excessive intake of Vitamin A (or retinoids like Isotretinoin) is a classic and high-yield cause of pseudotumor cerebri. It is thought to alter the resistance to CSF absorption at the arachnoid villi. * **Outdated Tetracycline:** Tetracyclines (including Minocycline and Doxycycline) are well-documented triggers. Outdated tetracyclines are also famously associated with **Fanconi Syndrome** (proximal renal tubular acidosis), but the class itself is a major cause of IIH. * **Nalidixic Acid:** This older quinolone antibiotic is a known causative agent of raised intracranial pressure, particularly in the pediatric population. **NEET-PG High-Yield Pearls:** * **Mnemonic for Causes (P-A-N-T-S):** **P**henytoin/Steroid withdrawal, **A**miodarone/Vitamin **A**, **N**alidixic acid, **T**etracyclines, **S**teroids (chronic use or withdrawal). * **Demographics:** Most common in obese females of childbearing age. * **Clinical Sign:** Look for **6th Cranial Nerve (Abducens)** palsy as a false localizing sign due to increased ICP. * **Treatment of Choice:** **Acetazolamide** (carbonic anhydrase inhibitor) to decrease CSF production.

Question 173: Which of the following drugs contains two sulfhydryl groups in a molecule?

A. BAL (Correct Answer)
B. EDTA
C. Pencillamine
D. None of the above

Explanation: **Explanation:** The correct answer is **BAL (British Anti-Lewisite)**, also known as **Dimercaprol**. **1. Why BAL is correct:** BAL is a classic heavy metal chelator. Chemically, it is **2,3-dimercapto-1-propanol**. The term "mercapto" refers to the **sulfhydryl (-SH) group**. As the name "di-mercapto" implies, each molecule contains **two sulfhydryl groups**. These groups act as ligands that bind to heavy metals (like arsenic, mercury, and gold), forming a stable, non-toxic, heterocyclic ring complex that is excreted in the urine. **2. Why other options are incorrect:** * **EDTA (Ethylenediaminetetraacetic acid):** This is a polyamino carboxylic acid. It acts as a hexadentate ligand but **does not contain sulfhydryl groups**. It chelates metals (primarily calcium and lead) through its nitrogen and oxygen atoms. * **Penicillamine:** While Penicillamine is a degradation product of penicillin and contains **one sulfhydryl group** (it is D-beta-beta-dimethylcysteine), it does not contain two. It is used primarily for Wilson’s disease (copper chelation) and cystinuria. **Clinical Pearls for NEET-PG:** * **BAL Administration:** It is highly lipid-soluble and must be administered via **deep intramuscular injection** in an oily vehicle (peanut oil). * **Contraindication:** BAL is contraindicated in **Iron and Cadmium poisoning** because the BAL-metal complex is nephrotoxic. * **Water-soluble analogs:** Succimer (DMSA) and Unithiol (DMPS) are water-soluble derivatives of BAL that can be given orally and have a better safety profile. * **Specific Antidote Rule:** BAL is the first-line chelator for **Arsenic, Mercury (acute), and Gold** poisoning. In **Lead poisoning**, it is often used in combination with EDTA (especially in lead encephalopathy).

Question 174: A patient with congestive heart failure was started on digoxin and diuretics. He later presents with bradycardia, GIT upset, and visual disturbances. His serum potassium was found to be 2.5 mEq/L. What is the most likely reason for these features?

A. Left ventricular aneurysm
B. Digoxin toxicity (Correct Answer)
C. Viral gastroenteritis
D. Hypokalemia

Explanation: ### Explanation **Correct Answer: B. Digoxin Toxicity** The patient presents with the classic triad of **Digoxin toxicity [1]**: 1. **Cardiac:** Bradycardia (due to increased vagal tone and slowed conduction through the AV node) [1]. 2. **Gastrointestinal:** Nausea, vomiting, and anorexia (earliest signs). 3. **Neurological/Visual:** Blurred vision and xanthopsia (yellow-green halos around lights). The underlying mechanism involves the inhibition of the **Na⁺/K⁺-ATPase pump**. The most critical factor in this scenario is the **hypokalemia (2.5 mEq/L)**, likely caused by the concurrent use of loop or thiazide diuretics. Since potassium and digoxin compete for the same binding site on the Na⁺/K⁺-ATPase pump, low extracellular potassium allows more digoxin to bind, significantly increasing its toxicity even if serum digoxin levels are within the "normal" therapeutic range. **Why incorrect options are wrong:** * **A. Left ventricular aneurysm:** This typically presents with persistent ST-elevation on ECG post-MI and heart failure symptoms, not the specific triad of GIT upset and visual changes. * **C. Viral gastroenteritis:** While it explains vomiting, it does not account for bradycardia, visual disturbances, or the specific drug interaction context. * **D. Hypokalemia:** While hypokalemia is present, it is the *precipitating factor* rather than the primary cause of the clinical syndrome. Hypokalemia itself usually causes muscle weakness or arrhythmias (like U-waves), but the specific combination of bradycardia and xanthopsia points directly to digoxin. **NEET-PG High-Yield Pearls:** * **Most common arrhythmia in Digoxin toxicity:** Ventricular Bigeminy [1]. * **Most characteristic/specific arrhythmia:** Atrial Tachycardia with AV block. * **Antidote:** Digoxin-specific antibody fragments (DigiFab). * **Electrolyte triggers:** Hypokalemia, Hypomagnesemia, and **Hypercalcemia** all predispose to toxicity. (Mnemonic: *Low K, Low Mg, High Ca*).

Question 175: Which drug is contraindicated in pregnancy?

A. Enalapril
B. Hydralazine
C. Frusemide (Correct Answer)
D. Aldactone

Explanation: **Explanation:** The correct answer is **Frusemide (C)**. While several drugs in this list have safety concerns, Frusemide is generally avoided in pregnancy because it can cause **placental hypoperfusion**. Diuretics reduce maternal plasma volume, which may compromise blood flow to the fetus, potentially leading to intrauterine growth restriction (IUGR). It is only used in rare, life-threatening situations like maternal pulmonary edema. **Analysis of Options:** * **A. Enalapril:** This is a classic **teratogen** (ACE inhibitor). It is contraindicated, especially in the 2nd and 3rd trimesters, as it causes fetal renal dysgenesis, oligohydramnios, and skull defects. However, in the context of this specific question (often sourced from standard textbooks like K.D. Tripathi), Frusemide is highlighted for its specific effect on placental perfusion. * **B. Hydralazine:** This is a **safe** and frequently used drug for the management of hypertensive emergencies in pregnancy (Preeclampsia/Eclampsia). It is a direct vasodilator. * **D. Aldactone (Spironolactone):** This is generally avoided due to its **anti-androgenic effects**, which can interfere with the sexual differentiation of a male fetus (feminization). **NEET-PG High-Yield Pearls:** * **Drug of Choice (DOC) for Chronic Hypertension in Pregnancy:** Labetalol (Alpha + Beta blocker). * **Other Safe Antihypertensives:** Methyldopa (central alpha-2 agonist), Nifedipine (CCB). * **Absolute Contraindications:** ACE inhibitors and ARBs (Renal issues), Statins (Teratogenic), Warfarin (Fetal Warfarin Syndrome/Chondrodysplasia punctata). * **Magnesium Sulfate ($MgSO_4$):** DOC for seizure prophylaxis and control in Eclampsia.

Question 176: Which schedule of the Drugs and Cosmetics Act mandates that a drug must be sold by retail only upon production of a prescription from a Registered Medical Practitioner?

A. Schedule H (Correct Answer)
B. Schedule M
C. Schedule P
D. Schedule W

Explanation: ### Explanation **Correct Option: A. Schedule H** The Drugs and Cosmetics Act (1940) and Rules (1945) classify drugs into various schedules to regulate their manufacture, sale, and distribution. **Schedule H** contains a list of "Prescription Drugs." By law, these drugs can only be sold by retail upon the production of a valid prescription from a **Registered Medical Practitioner (RMP)**. The label of these drugs must display the symbol ‘Rx’ and a warning stating that they are not to be sold without a prescription. **Analysis of Incorrect Options:** * **Schedule M:** This schedule specifies the **Good Manufacturing Practices (GMP)** and requirements for factory premises, plants, and equipment for pharmaceutical products. * **Schedule P:** This deals with the **Life period (expiry date)** and storage conditions of various drugs (e.g., Insulin, Antibiotics). * **Schedule W:** This previously listed drugs that were to be marketed under **Generic names** only (though this schedule has largely been omitted/merged in recent amendments). **High-Yield Clinical Pearls for NEET-PG:** * **Schedule H1:** Introduced in 2013 to curb the misuse of antibiotics and anti-TB drugs. It requires the pharmacist to maintain a separate register with patient and prescriber details, retained for 3 years. * **Schedule X:** Includes psychotropic drugs and narcotics (e.g., Ketamine, Amphetamines). These require a double-copy prescription, and the pharmacist must keep one copy for 2 years. * **Schedule G:** Drugs that must be taken under **medical supervision** (e.g., Metformin, Antihistamines) but do not necessarily require a formal prescription for every refill like Schedule H. * **Schedule Y:** Guidelines for **Clinical Trials** and import/manufacture of new drugs.

Question 177: All of the following drugs can induce a Systemic Lupus Erythematosus (SLE)-like syndrome except?

A. Isoniazid
B. Chloramphenicol (Correct Answer)
C. Hydralazine
D. Sulphonamides

Explanation: **Explanation:** Drug-Induced Lupus Erythematosus (DILE) is a clinical syndrome that mimics idiopathic SLE, typically characterized by arthralgia, myalgia, fever, and pleuritis, but notably sparing the kidneys and CNS. **Why Chloramphenicol is the Correct Answer:** Chloramphenicol is a broad-spectrum antibiotic primarily associated with **Bone Marrow Suppression** (dose-dependent) and **Aplastic Anemia** (idiosyncratic). It is also known for causing **Gray Baby Syndrome** in neonates. It does not have a known association with inducing an SLE-like syndrome. **Analysis of Incorrect Options:** * **Hydralazine:** This is the drug with the **highest risk** of inducing DILE. The risk is significantly higher in "slow acetylators" as the drug is metabolized by the N-acetyltransferase (NAT) enzyme. * **Isoniazid (INH):** A primary anti-tubercular drug that frequently induces antinuclear antibodies (ANA). Like hydralazine, it is metabolized by acetylation and can trigger lupus-like symptoms. * **Sulphonamides:** These drugs are known triggers for various hypersensitivity reactions, including DILE and Stevens-Johnson Syndrome (SJS). **NEET-PG High-Yield Pearls:** 1. **Classic Triad of DILE Drugs:** Remember the mnemonic **"SHIP"** — **S**ulphonamides/Sulfasalazine, **H**ydralazine, **I**soniazid, and **P**rocainamide. 2. **Serology:** The hallmark of DILE is the presence of **Anti-Histone Antibodies** (>95% of cases). Unlike idiopathic SLE, Anti-dsDNA antibodies are usually absent. 3. **Metabolism Link:** DILE is most common in **Slow Acetylators**. 4. **Management:** Symptoms typically resolve spontaneously within weeks after **discontinuing** the offending drug.

Question 178: In chronic lead poisoning, which of the following is elevated?

A. Porphobilinogen
B. 6-amino levulinic acid (Correct Answer)
C. Bilirubin
D. Urobilinogen

Explanation: **Explanation:** Lead poisoning (Plumbism) interferes with the heme biosynthetic pathway by inhibiting two key enzymes: **$\delta$-aminolevulinic acid dehydratase (ALAD)** and **Ferrochelatase**. 1. **Why Option B is correct:** Lead directly inhibits the enzyme **$\delta$-aminolevulinic acid dehydratase (ALAD)**. This enzyme is responsible for converting $\delta$-aminolevulinic acid (ALA) into porphobilinogen. When ALAD is inhibited, its substrate, **$\delta$-aminolevulinic acid (ALA)**, accumulates in the blood and is excreted in excess in the urine. This is a hallmark biochemical finding in lead toxicity. 2. **Why other options are incorrect:** * **Porphobilinogen (A):** This is the product of the reaction catalyzed by ALAD. Since ALAD is inhibited, porphobilinogen levels actually decrease or remain low. (Elevated porphobilinogen is characteristic of Acute Intermittent Porphyria). * **Bilirubin (C) & Urobilinogen (D):** These are products of heme degradation. While lead can cause a mild hemolytic anemia, these markers are not specific to lead poisoning and do not represent the primary enzymatic block in the heme pathway. **High-Yield Clinical Pearls for NEET-PG:** * **Enzymes Inhibited:** ALAD and Ferrochelatase (leads to elevated **Free Erythrocyte Protoporphyrin/Zinc Protoporphyrin**). * **Hematological Finding:** Microcytic hypochromic anemia with **Basophilic Stippling** (due to inhibition of pyrimidine 5'-nucleotidase). * **Clinical Signs:** Burtonian lines (blue-purple gums), Lead colic, and "Wrist drop/Foot drop" (peripheral neuropathy). * **Treatment of Choice:** Oral **Succimer** (DMSA) for mild-moderate cases; **Ca-EDTA** or **Dimercaprol** (BAL) for severe/encephalopathic cases.

Question 179: Which of the following drugs is the longest-acting for overactive bladder?

A. Oxybutynin
B. Trospium
C. Solifenacin (Correct Answer)
D. Flavoxate

Explanation: **Explanation:** The management of overactive bladder (OAB) primarily involves **M3-selective muscarinic antagonists**. The duration of action and dosing frequency are critical for patient compliance and minimizing side effects. **Why Solifenacin is correct:** **Solifenacin** is a competitive muscarinic receptor antagonist with a high affinity for the M3 receptor. It is characterized by a significantly **long elimination half-life (approx. 45–68 hours)**, allowing for convenient **once-daily dosing**. This prolonged duration of action provides stable plasma concentrations, making it the longest-acting agent among the options provided. **Analysis of Incorrect Options:** * **Oxybutynin:** This is a non-selective muscarinic antagonist. The immediate-release (IR) formulation has a very short half-life (2–3 hours) requiring multiple daily doses. Even the extended-release (ER) version does not match the inherent pharmacological half-life of Solifenacin. * **Trospium:** A quaternary ammonium compound with a half-life of about 10–20 hours. While it has the advantage of not crossing the blood-brain barrier (reducing CNS side effects), it is shorter-acting than Solifenacin. * **Flavoxate:** This is a direct-acting smooth muscle relaxant (PDE inhibitor) rather than a potent anticholinergic. It has a very short duration of action and is generally considered less effective for OAB compared to M3-selective antagonists. **High-Yield Clinical Pearls for NEET-PG:** * **M3 Selectivity:** Solifenacin and Darifenacin are M3-selective, leading to fewer systemic side effects like xerostomia (dry mouth) compared to Oxybutynin. * **CNS Safety:** **Trospium** is the drug of choice for OAB in elderly patients with cognitive impairment/dementia because its quaternary structure prevents it from crossing the blood-brain barrier. * **Mirabegron:** A **β3-adrenoceptor agonist** used as an alternative for OAB, especially in patients who cannot tolerate anticholinergic side effects.

Question 180: What is the treatment of choice for opioid overdose?

A. Naloxone IV (Correct Answer)
B. Nalorphine IV
C. Haemodialysis
D. Forced alkaline diuresis

Explanation: ### Explanation **1. Why Naloxone IV is the Correct Answer:** Naloxone is a **pure opioid antagonist** with a high affinity for $\mu$ (mu), $\kappa$ (kappa), and $\delta$ (delta) receptors. It works by competitively displacing opioids from their receptors, rapidly reversing life-threatening symptoms like respiratory depression and coma. It is administered intravenously (IV) for the fastest onset of action (1–2 minutes). Because it has no agonist activity, it does not cause respiratory depression even in high doses. **2. Why the Other Options are Incorrect:** * **Nalorphine IV:** This is a **mixed agonist-antagonist**. While it can antagonize morphine, it possesses inherent agonist activity which can worsen respiratory depression or cause dysphoria and hallucinations. It is no longer used for overdose. * **Haemodialysis:** Opioids generally have a **large volume of distribution ($V_d$)** and are highly lipid-soluble. Dialysis is ineffective for drugs that are sequestered in tissues rather than remaining in the plasma. * **Forced Alkaline Diuresis:** This technique is used to enhance the excretion of weak acids (e.g., Salicylates, Phenobarbitone). Opioids are weak bases and are primarily metabolized by the liver, not excreted unchanged by the kidneys, making diuresis ineffective. **3. High-Yield Clinical Pearls for NEET-PG:** * **Short Half-life:** Naloxone has a shorter duration of action (30–90 mins) than most opioids (e.g., Morphine, Methadone). **Renarcotization** (re-sedation) can occur, necessitating repeated doses or a continuous infusion. * **Diagnostic Use:** Naloxone is used in the "Coma Cocktail" for patients with an unknown cause of unconsciousness. * **Opioid Withdrawal:** In opioid-dependent individuals, Naloxone can precipitate an **acute withdrawal syndrome** (miosis, rhinorrhea, lacrimation, and "gooseflesh"). * **Oral Alternative:** **Naltrexone** is a long-acting oral antagonist used for the maintenance of opioid-free states (de-addiction), not for acute overdose.

Practice by Chapter

Principles of Clinical Pharmacology

Practice Questions

Therapeutic Drug Monitoring

Practice Questions

Drug Toxicity and Overdose

Practice Questions

Antidotes and Their Applications

Practice Questions

Management of Drug Poisoning

Practice Questions

Drug-Induced Liver Injury

Practice Questions

Drug-Induced Kidney Injury

Practice Questions

Drug-Induced Blood Dyscrasias

Practice Questions

Drug-Induced QT Prolongation

Practice Questions

Pharmacovigilance

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free